This FTSE 100 stock recently unveiled plans to almost double revenue to $80bn by 2030. Our writer explores what this means for investors. The post Is this FTSE 100 behemoth about to make investors rich all over again? appeared first on The Motley Fool UK.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.